Patofisiologi Karsinoma Sel Renal

Oleh :

Sunita

Pengetahuan tentang patofisiologi karsinoma sel renal atau renal cell carcinoma (RCC) telah berkembang pesat sejak dekade 1990 dan telah berhasil mengidentifikasi kaitan RCC dengan berbagai sindrom familial, gen penekan tumor, dan onkogen. Pemahaman tentang sifat berbagai subtipe RCC yang berbeda tak hanya mempengaruhi klasifikasi histologi tumor, namun juga bermanfaat mengarahkan tata laksana pasien yang diperantarai oleh terapi target.

Mayoritas RCC bersifat sporadis dan melibatkan mutasi pada kedua alel pada gen tertentu. Sementara itu, pada sebagian kecil kasus, RCC bersifat familial yang ditandai mutasi bawaan pada satu alel dan disfungsi alel lainnya akibat mutasi lanjutan.

Karsinoma Sel Renal Sebagai Suatu Gangguan Genetik

Referensi

1. D’Avella C, Abbosh P, Pal SK, Geynisman DM. Mutations in renal cell carcinoma. Urol Oncol Semin Orig Investig [Internet]. 2018 Nov; Available from: https://doi.org/10.1016/j.urolonc.2018.10.027
2. Moch H. An overview of renal cell cancer: Pathology and genetics. Semin Cancer Biol [Internet]. 2013;23(1):3–9. Available from: http://dx.doi.org/10.1016/j.semcancer.2012.06.006
3. Clark PE. The role of VHL in ccRCC and its relation to targeted therapy. Kidney Int. 2009;76(9):939–45.
4. Shen C, Kaelin WG. The VHL/HIF axis in clear cell renal carcinoma. Semin Cancer Biol [Internet]. 2013;23(1):18–25. Available from: http://dx.doi.org/10.1016/j.semcancer.2012.06.001
5. Atkins MB, Tannir NM. Current and emerging therapies for first-line treatment of metastatic clear cell renal cell carcinoma. Cancer Treat Rev [Internet]. 2018 Nov;70:127–37. Available from: https://doi.org/10.1016/j.ctrv.2018.07.009
6. Jonasch E, Park E, Thamake S, Hirmand M, Srinivasan R. 921TiPAn open-label phase II study to evaluate PT2977 for the treatment of von hippel-lindau disease associated renal cell carcinoma. Ann Oncol [Internet]. 2018 Oct 1;29(suppl_8). Available from: https://academic.oup.com/annonc/article/doi/10.1093/annonc/mdy283.130/5140823
7. Martínez-Sáez O, Gajate Borau P, Alonso-Gordoa T, Molina-Cerrillo J, Grande E. Targeting HIF-2 α in clear cell renal cell carcinoma: A promising therapeutic strategy. Crit Rev Oncol Hematol [Internet]. 2017 Mar;111:117–23. Available from: http://dx.doi.org/10.1016/j.critrevonc.2017.01.013
8. Brugarolas J. PBRM1 and BAP1 as novel targets for renal cell carcinoma. Cancer J [Internet]. 19(4):324–32. Available from: http://www.ncbi.nlm.nih.gov/pubmed/23867514
9. Reisman D, Glaros S, Thompson EA. The SWI/SNF complex and cancer. Oncogene [Internet]. 2009 Apr 9;28(14):1653–68. Available from: http://www.ncbi.nlm.nih.gov/pubmed/19234488
10. Santoni M, Massari F, Di Nunno V, Conti A, Cimadamore A, Scarpelli M, et al. Immunotherapy in renal cell carcinoma: latest evidence and clinical implications. Drugs Context. 2018;7:1–8.
11. Atkins MB, Clark JI, Quinn DI. Immune checkpoint inhibitors in advanced renal cell carcinoma: experience to date and future directions. Ann Oncol [Internet]. 2017 Jul;28(7):1484–94. Available from: https://academic.oup.com/annonc/article-lookup/doi/10.1093/annonc/mdx151
12. Farhood B, Najafi M, Mortezaee K. CD8 + cytotoxic T lymphocytes in cancer immunotherapy: A review. J Cell Physiol [Internet]. 2018 Nov 22; Available from: http://doi.wiley.com/10.1002/jcp.27782
13. Gouttefangeas C, Stenzl A, Stevanović S, Rammensee H-G. Immunotherapy of renal cell carcinoma. Cancer Immunol Immunother [Internet]. 2007 Jan;56(1):117–28. Available from: http://www.ncbi.nlm.nih.gov/pubmed/16676181
14. Kim HR, Ha S-J, Hong MH, Heo SJ, Koh YW, Choi EC, et al. PD-L1 expression on immune cells, but not on tumor cells, is a favorable prognostic factor for head and neck cancer patients. Sci Rep [Internet]. 2016 Dec 14;6(1):36956. Available from: http://www.nature.com/articles/srep36956
15. Ueda K, Suekane S, Kurose H, Chikui K, Nakiri M, Nishihara K, et al. Prognostic value of PD-1 and PD-L1 expression in patients with metastatic clear cell renal cell carcinoma. Urol Oncol Semin Orig Investig [Internet]. 2018 Nov;36(11):499.e9-499.e16. Available from: https://linkinghub.elsevier.com/retrieve/pii/S1078143918302515
16. Xu F, Xu L, Wang Q, An G, Feng G, Liu F. Clinicopathological and prognostic value of programmed death ligand-1 (PD-L1) in renal cell carcinoma: a meta-analysis. Int J Clin Exp Med [Internet]. 2015;8(9):14595–603. Available from: http://www.ncbi.nlm.nih.gov/pubmed/26628942
17. Leite KRM, Reis ST, Junior JP, Zerati M, Gomes D de O, Camara-Lopes LH, et al. PD-L1 expression in renal cell carcinoma clear cell type is related to unfavorable prognosis. Diagn Pathol [Internet]. 2015 Oct 15;10:189. Available from: http://www.ncbi.nlm.nih.gov/pubmed/26470780
18. Altman BJ, Stine ZE, Dang C V. From Krebs to Clinic : Glutamine Metabolism to Cancer Therapy. 2017;16(10):619–34.
19. Wettersten HI, Aboud OA, Jr PNL, Weiss RH. Metabolic reprogramming in clear cell renal cell carcinoma. Nat Publ Gr [Internet]. 2017;13(7):410–9. Available from: http://dx.doi.org/10.1038/nrneph.2017.59
20. Nguyen T, Le A. The Metabolism of Renal Cell Carcinomas and Liver Cancer. 2018;107–18.

(Konten ini khusus untuk dokter. Registrasi untuk baca selengkapnya)

Masuk atau Daftar

Nomor Ponsel Sudah Terdaftar

Masuk dengan Email

Masuk dengan Email

Masuk dengan Facebook

Patofisiologi Karsinoma Sel Renal

Karsinoma Sel Renal Sebagai Suatu Gangguan Genetik

Referensi

Masuk atau Daftar